312 related articles for article (PubMed ID: 31534547)
1. A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice.
Zhang D; Baldwin P; Leal AS; Carapellucci S; Sridhar S; Liby KT
Theranostics; 2019; 9(21):6224-6238. PubMed ID: 31534547
[TBL] [Abstract][Full Text] [Related]
2. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
3. Sustained Release Talazoparib Implants for Localized Treatment of
Belz JE; Kumar R; Baldwin P; Ojo NC; Leal AS; Royce DB; Zhang D; van de Ven AL; Liby KT; Sridhar S
Theranostics; 2017; 7(17):4340-4349. PubMed ID: 29158830
[TBL] [Abstract][Full Text] [Related]
4. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline
de Bono J; Ramanathan RK; Mina L; Chugh R; Glaspy J; Rafii S; Kaye S; Sachdev J; Heymach J; Smith DC; Henshaw JW; Herriott A; Patterson M; Curtin NJ; Byers LA; Wainberg ZA
Cancer Discov; 2017 Jun; 7(6):620-629. PubMed ID: 28242752
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors.
Mittra A; Coyne GHOS; Zlott J; Kummar S; Meehan R; Rubinstein L; Juwara L; Wilsker D; Ji J; Miller B; Navas T; Ferry-Galow KV; Voth AR; Chang TC; Jiwani S; Parchment RE; Doroshow JH; Chen AP
Cancer Chemother Pharmacol; 2024 Mar; 93(3):177-189. PubMed ID: 38010394
[TBL] [Abstract][Full Text] [Related]
6. Talazoparib to treat BRCA-positive breast cancer.
Guney Eskiler G
Drugs Today (Barc); 2019 Jul; 55(7):459-467. PubMed ID: 31347614
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
[TBL] [Abstract][Full Text] [Related]
8. Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
McCann KE
Future Oncol; 2019 May; 15(15):1707-1715. PubMed ID: 30912451
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline
Litton JK; Scoggins ME; Hess KR; Adrada BE; Murthy RK; Damodaran S; DeSnyder SM; Brewster AM; Barcenas CH; Valero V; Whitman GJ; Schwartz-Gomez J; Mittendorf EA; Thompson AM; Helgason T; Ibrahim N; Piwnica-Worms H; Moulder SL; Arun BK
J Clin Oncol; 2020 Feb; 38(5):388-394. PubMed ID: 31461380
[TBL] [Abstract][Full Text] [Related]
10. Talazoparib: First Global Approval.
Hoy SM
Drugs; 2018 Dec; 78(18):1939-1946. PubMed ID: 30506138
[TBL] [Abstract][Full Text] [Related]
11. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
Guney Eskiler G; Cecener G; Egeli U; Tunca B
Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
[TBL] [Abstract][Full Text] [Related]
12. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
[TBL] [Abstract][Full Text] [Related]
13. Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice.
Zhang D; Singh B; Moerland J; Mitchell O; Lockwood L; Carapellucci S; Sridhar S; Liby KT
Sci Rep; 2021 Jan; 11(1):1234. PubMed ID: 33441637
[TBL] [Abstract][Full Text] [Related]
14. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
Jerez Y; Márquez-Rodas I; Aparicio I; Alva M; Martín M; López-Tarruella S
Drugs; 2020 Feb; 80(2):131-146. PubMed ID: 31823331
[TBL] [Abstract][Full Text] [Related]
15. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
[TBL] [Abstract][Full Text] [Related]
16. Talazoparib for BRCA-mutated advanced breast cancer.
Gunjur A
Lancet Oncol; 2018 Oct; 19(10):e511. PubMed ID: 30146245
[No Abstract] [Full Text] [Related]
17. Therapeutic potential of the PI3K inhibitor LY294002 and PARP inhibitor Talazoparib combination in BRCA-deficient triple negative breast cancer cells.
Guney Eskiler G; Ozturk M
Cell Signal; 2022 Mar; 91():110229. PubMed ID: 34958867
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Turk AA; Wisinski KB
Cancer; 2018 Jun; 124(12):2498-2506. PubMed ID: 29660759
[TBL] [Abstract][Full Text] [Related]
19. Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Węsierska-Gądek J; Mauritz M; Mitulovic G; Cupo M
J Cell Biochem; 2015 Dec; 116(12):2824-39. PubMed ID: 25981734
[TBL] [Abstract][Full Text] [Related]
20. Advances in PARP inhibitors for the treatment of breast cancer.
Dizdar O; Arslan C; Altundag K
Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
